Home・Akciju saraksts・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Slēgts

SektorsVeselības aprūpe

3.22 -1.23

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.13

Max

3.25

Galvenie mērījumi
By Trading Economics
Ienākumi	4.1M -5.7M
EPS	-0.06
Darbinieki	34
EBITDA	-821K -6.5M

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 18. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	82M 314M
Iepriekšējā atvēršanas cena	4.45
Iepriekšējā slēgšanas cena	3.22

Ziņu noskaņojums

By Acuity

50%

163 / 340 Rangs Healthcare

Anavex Life Sciences Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 14. aug. 20:13 UTC

Anavex Life Sciences shares are lower in after-market hours, influenced by disappointing U.S. retail sales data and declining consumer sentiment.

2026. g. 13. aug. 22:51 UTC

Anavex Life Sciences Corp shares are lower in after-market hours, continuing a trend of declines over three consecutive sessions. No specific news was identified.

2026. g. 12. aug. 19:46 UTC

Anavex Life Sciences Corp shares are lower today, continuing a decline since Tuesday's close, despite remaining above the 20-day moving average.

2026. g. 11. aug. 23:22 UTC

Anavex Life Sciences Corp is trading lower in after-market hours with no specific news. The stock remains well above its 20-day moving average.

2026. g. 10. aug. 19:46 UTC

Anavex Life Sciences is trading higher today, despite no specific news. Broader market sentiment is influenced by upcoming inflation data and Fed policy expectations.

2026. g. 7. aug. 22:16 UTC

Anavex Life Sciences Corp is higher in after-market trading, continuing a trend of gains over the last seven sessions, despite no specific news identified.

2026. g. 6. aug. 23:51 UTC

Anavex Life Sciences Corp is rising in after-market trading, reaching a high shortly after the market closed, despite no specific news driving the increase.

2026. g. 5. aug. 21:01 UTC

Anavex Life Sciences shares fell in after-market trading, declining significantly despite being above its 20-day moving average and near the top of its one-month range.

2026. g. 4. aug. 19:51 UTC

Anavex Life Sciences Corp is rising amid broader market strength and a decline in crude oil prices, despite pulling back from earlier session highs.

2026. g. 3. aug. 20:02 UTC

News

Anavex Life Sciences Corp announces board changes amid a proxy fight, urging stockholders to reject PVG Asset Management's attempt to replace the board. Shares are higher.

2026. g. 30. jūl. 19:39 UTC

Event

Anavex Life Sciences reported Q2 earnings of -$0.06 per share, beating expectations. Shares remain higher since Wednesday's close despite pulling back from session highs.

2026. g. 29. jūl. 22:31 UTC

Anavex Life Sciences Corp shares are higher in after-market trading, reflecting broader market gains following the Federal Reserve's decision to maintain interest rates.

2026. g. 28. jūl. 21:01 UTC

Anavex Life Sciences Corp shares are lower in after-market hours, currently 1.45% below their 20-day moving average. No specific news was identified.

2026. g. 27. jūl. 20:07 UTC

Anavex Life Sciences Corp shares are higher during Monday's session, maintaining gains since Friday amid broader market trends and easing geopolitical tensions.

2026. g. 24. jūl. 17:46 UTC

Anavex Life Sciences Corp shares are lower today, continuing a decline since Thursday's close, with no specific news identified to explain the move.

2026. g. 21. jūl. 19:51 UTC

Anavex Life Sciences is rising during Tuesday's session, recovering from a pre-market low. Broader market sentiment is supported by positive earnings from General Motors and Novartis.

Salīdzinājums

Cenas izmaiņa

Anavex Life Sciences Corp Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Anavex Life Sciences Corp — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

163 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.